Cell Death Dis: FBI-1 enhances resistance to triple-negative breast cancer through the miR-30c/PXR path.

FBI-1, also known as LRF, OCZF, and ZBTB7A, is considered an important primary cancer gene and plays a vital role in human malignancies.
FBI-1 can not only promote the proliferation or metastasis of human cancer cells by suppressing tumor inhibitors, but also induce cancer cell resistance to anti-tumor drugs.
studies have shown that FBI-1 has been expressed in several human cancers, including lung, hepatocellular, breast and colorectal cancers.
, the FBI-1 may be a potential and valuable target for human malignancy treatment.
in the study, researchers found that FBI-1 was able to increase the resistance of triple-negative breast cancer (TNBC) cells to chemotherapy drugs by suppressing the expression levels of micoRNA-30c targeting PXR (pregnancy X-patient).
the relationship between FBI-1 and PXR path factors showed that in TNBC, the level of expression of FBI-1 was positively related to the level of PXR and its downstream drug resistance-related genes.
THE FBI-1 can raise the expression of PXR and enhance the activation level of the PXR path.
miR-30c can reduce the expression level of PXR by targeting the PXR's 3'-UTR, while the FBI-1 can increase the expression of PXR by suppressing the expression level of miR-30c.
by mediating the miR-30c/PXR path, the FBI-1 accelerates the removal or elimination of anti-tumor drugs in TNBC cells, ultimately inducing cell resistance.
THE FBI-1 accelerated the removal of Olapani from TNBC cells, the results showed that the miR-30c/PXR path path is involved in the resistance of FBI-1-mediated TNBC cells.
.